

REC Reference	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number of Patients Agreed	Maximum Number of Patients Agreed	Target Date to Recruit Patients Agreed?	Date Agreed to Recruit Target Number of Patients	Total Number of Patients Recruited at Agreed Target Date	Date Trial Closed to Recruitment	Total Number of Study Participants Recruited	Reason for Closure of the Trial
14/SC/1161	155743	3708 Card e-ULTIMASTER Registry	Number Agreed	50	50	Date Agreed	03/09/2018	53	03/05/2018	53	Recruitment Finished
16/LO/0675	147355	CANC 5613	Range Agreed	1	2	Date Agreed	31/05/2018	2	29/06/2018	2	Recruitment Finished
17/LO/1247	228533	Rova-T as 2nd Line Therapy (TAHOE)	Number Agreed	2	2	Date Agreed	31/01/2019	0	26/07/2018	0	Withdrawn By Sponsor
16/LO/1625	173719	Assessment of real life care (ARIADNE)	Number Agreed	20	20	Date Agreed	04/11/2018	26	28/03/2018	26	Recruitment Finished
17/EM/0425	236800	Retrospective review of current treatment pathways for MF in the UK	Number Agreed	10	10	Date Agreed	30/04/2018	26	12/07/2018	26	Recruitment Finished
14/SC1350	166544	CANC 3619	Number Agreed	3	3	Date Agreed	01/03/2019	11	31/03/2019	11	Recruitment Finished
15/SC/0303	167788	CANC - 4432 - Revlimid (lenalidomide) NIS Post	Number Agreed	1	1	Date Agreed	29/03/2019	2	29/03/2019	2	Recruitment Finished
16/EM/0193	190690	CARD 4843	Number Agreed	12	12	Date Agreed	12/11/2018	132	12/11/2018	132	Recruitment Finished
17/SC/0253	226685	MonarchE: Phase 3 Study of Abemaciclib in Breast Cancer (JPCF)	Number Agreed	4	4	Date Agreed	15/02/2019	3	15/02/2019	3	Withdrawn By Sponsor